Luigi Celio Selected Research

Nausea

3/2024	Characteristics of nausea and its impact on health-related quality of life in cisplatin-treated patients receiving dexamethasone-sparing prophylaxis: an analysis of the LUNG-NEPA study.
1/2023	Dexamethasone-sparing regimens with NEPA (netupitant/palonosetron) for the prevention of chemotherapy-induced nausea and vomiting in older patients (>65 years) fit for cisplatin: A sub-analysis from a phase 3 study.
1/2023	Exploratory analysis of the effect of a dexamethasone-sparing regimen for prophylaxis of cisplatin-induced emesis on food intake (LUNG-NEPA study).
9/2022	Efficacy of the dexamethasone-sparing triplet regimen for preventing cisplatin-induced emesis: a combined analysis.
8/2022	Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 study.
1/2022	Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice.
10/2021	Dexamethasone-Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High-Dose Cisplatin: A Randomized Noninferiority Study.
1/2021	Practice Patterns for Prevention of Chemotherapy-Induced Nausea and Vomiting and Antiemetic Guideline Adherence Based on Real-World Prescribing Data.
3/2020	Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study.
3/2020	Oral Capecitabine-Vinorelbine is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Luigi Celio Research Topics

Disease

31	Nausea 03/2024 - 07/2008
31	Vomiting 01/2023 - 07/2008
14	Breast Neoplasms (Breast Cancer) 01/2021 - 05/2003
13	Neoplasms (Cancer) 09/2022 - 12/2002
2	Stomach Neoplasms (Stomach Cancer) 01/2009 - 12/2002
1	Weight Loss (Weight Reduction) 01/2023
1	Disease Progression 09/2022
1	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 09/2022
1	Cholangiocarcinoma 07/2021
1	Diarrhea 03/2020
1	Circulating Neoplastic Cells 01/2020
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2020
1	Lymphatic Metastasis 01/2020
1	Neutropenia 01/2019
1	Colorectal Neoplasms (Colorectal Cancer) 01/2009
1	Adenocarcinoma 12/2002

Drug/Important Bio-Agent (IBA)

22	Dexamethasone (Maxidex)FDA LinkGeneric 03/2024 - 07/2008
22	Palonosetron (Aloxi)FDA Link 03/2024 - 07/2008
14	AntiemeticsIBA 03/2024 - 07/2008
9	Cisplatin (Platino)FDA LinkGeneric 03/2024 - 07/2008
8	netupitantIBA 03/2024 - 08/2018
6	AnthracyclinesIBA 01/2021 - 02/2013
6	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2021 - 02/2013
4	Thrombin FDA Link 09/2022 - 01/2020
4	Aprepitant (Emend)FDA Link 01/2020 - 07/2008
3	Carboplatin (JM8)FDA LinkGeneric 01/2021 - 01/2019
3	Capecitabine (Xeloda)FDA Link 03/2020 - 04/2005
3	Hormones (Hormone)IBA 03/2020 - 05/2003
3	Olanzapine (Zyprexa)FDA Link 06/2019 - 01/2017
2	fibrin fragment D (D-dimer)IBA 09/2022 - 01/2020
2	Biomarkers (Surrogate Marker)IBA 09/2022 - 01/2020
2	Hemostatics (Antihemorrhagics)IBA 09/2022 - 01/2020
2	EmeticsIBA 10/2021 - 01/2017
2	Gemcitabine FDA Link 07/2021 - 01/2019
2	5-HT3 Serotonin Receptors (5 HT3 Receptor)IBA 01/2021 - 01/2020
2	Neurokinin-1 Receptor AntagonistsIBA 01/2021 - 07/2019
2	Paclitaxel (Taxol)FDA LinkGeneric 06/2019 - 01/2013
2	Serotonin (5 Hydroxytryptamine)IBA 01/2017 - 07/2014
2	Toremifene (Fareston)FDA Link 06/2008 - 12/2004
1	ON 01910IBA 07/2021
1	Phosphotransferases (Kinase)IBA 07/2021
1	Radiation-Sensitizing AgentsIBA 07/2021
1	Transaminases (Aminotransferases)IBA 03/2020
1	Vinorelbine (Navelbine)FDA LinkGeneric 03/2020
1	Epithelial Cell Adhesion MoleculeIBA 01/2020
1	Fibrinogen (Factor I)FDA Link 01/2020
1	AntithrombinsIBA 01/2020
1	Phenobarbital (Luminal)FDA Link 01/2020
1	Prothrombin (Factor II)IBA 01/2020
1	Metoclopramide (Reglan)FDA LinkGeneric 01/2017
1	Streptozocin (Streptozotocin)FDA Link 01/2017
1	Carmustine (FIVB)FDA Link 01/2017
1	Mechlorethamine (Nitrogen Mustard)FDA Link 01/2017
1	Dacarbazine (DIC)FDA LinkGeneric 01/2017
1	Serotonin 5-HT3 Receptor AntagonistsIBA 10/2013
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2013
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2013
1	fosaprepitant FDA Link 01/2013
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2009
1	Irinotecan (Camptosar)FDA LinkGeneric 01/2009
1	Complementary DNA (cDNA)IBA 06/2008
1	Estrogens (Estrogen)FDA Link 06/2008
1	Estrogen Receptor alphaIBA 06/2008
1	Estrogen ReceptorsIBA 06/2008
1	Estrogen Receptor betaIBA 12/2004
1	Messenger RNA (mRNA)IBA 12/2004
1	Estrogen Receptor Modulators (Antiestrogen)IBA 12/2004
1	Anastrozole (Arimidex)FDA LinkGeneric 05/2003
1	Letrozole (Femara)FDA LinkGeneric 05/2003
1	Insulin-Like PeptidesIBA 05/2003
1	exemestane (Aromasin)FDA Link 05/2003
1	Aromatase InhibitorsIBA 05/2003
1	Aminoglutethimide (Cytadren)FDA Link 05/2003
1	Interleukin-6 (Interleukin 6)IBA 05/2003
1	Pemetrexed (MTA)FDA Link 12/2002
1	Folic Acid AntagonistsIBA 12/2002

Therapy/Procedure

32	Drug Therapy (Chemotherapy) 03/2024 - 12/2002
9	Therapeutics 09/2022 - 12/2002
1	Adjuvant Chemotherapy 01/2020
1	Induction Chemotherapy 01/2020
1	Radiotherapy 08/2018
1	Aftercare (After-Treatment) 12/2004